Open Access
03-01-2024 | COVID-19 | Original Article
Characteristics and prognosis of patients with COVID-19 and hematological diseases in Japan: a cross-sectional study
Authors:
Daisuke Minakata, Tomoyuki Uchida, Aya Nakano, Ken Takase, Nodoka Tsukada, Hiroshi Kosugi, Eri Kawata, Takahiko Nakane, Hiroyuki Takahashi, Tomoyuki Endo, Satoshi Nishiwaki, Hideaki Fujiwara, Akiko M. Saito, Toshiki I. Saito, Koichi Akashi, Itaru Matsumura, Kinuko Mitani
Published in:
International Journal of Hematology
|
Issue 2/2024
Login to get access
Abstract
The Japanese Society of Hematology performed an observational cross-sectional study to clarify the morbidity, prognosis, and prognostic factors in patients with COVID-19 with hematological diseases (HDs) in Japan. The study included patients with HDs who enrolled in our epidemiological survey and had a COVID-19 diagnosis and a verified outcome of up to 2 months. The primary endpoints were characteristics and short-term prognosis of COVID-19 in patients with HDs. A total of 367 patients from 68 institutes were enrolled over 1 year, and the collected data were analyzed. The median follow-up among survivors was 73 days (range, 1–639 days). The 60-day overall survival (OS) rate was 86.6%. In the multivariate analysis, albumin ≤ 3.3 g/dL and a need for oxygen were independently associated with inferior 60-day OS rates (hazard ratio [HR] 4.026, 95% confidence interval (CI) 1.954–8.294 and HR 14.55, 95% CI 3.378–62.64, respectively), whereas 60-day survival was significantly greater in patients with benign rather than malignant disease (HR 0.095, 95% CI 0.012–0.750). Together, these data suggest that intensive treatment may be necessary for patients with COVID-19 with malignant HDs who have low albumin levels and require oxygen at the time of diagnosis.